2seventy bio Inc. shares (NASDAQ:TSVT) rose 15% or 52 cents, to close Jan. 30 at $4.01 on word that the Cambridge, Mass.-based firm is selling its R&D pipeline to Regeneron Pharmaceuticals Inc., which will move the work forward by way of a new company called Regeneron Cell Medicines.
Institute of Cancer Research UK has described lysyl oxidase homolog 2 (LOXL2) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase ligand binding moiety covalently linked to an histone deacetylase 6 (HDAC6)/8 (HDAC8)-targeting moiety through a linker.
Zentaur Therapeutics USA Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Transcode Therapeutics Inc. has entered into a co-research agreement with Debiopharm SA that will bring together Transcode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
Researchers from Shanghai Xianhui Pharmaceutical Co. Ltd. have detailed the discovery and preclinical characterization of novel photosensitizers as candidates for photodynamic therapy (PDT) and photodiagnosis in cancer.
Hookipa Pharma Inc.’s nearly $1 billion collaboration with Roche Holding AG dissolved along with 30% of the company’s staff. The New York-based company said Roche ended the October 2022 deal involving the HB-700 program in treating KRAS mutated cancers but did not say why the agreement fell apart. Leerink Partners analyst Andrew Berens wrote Jan. 29 that the firm spoke to management, which indicated the program was progressing according to plan and that Roche's decision was based more on its own internal pipeline strategy, lessening its focus on oncology after high profile failures vs. the program having issues in development.
The U.S. FDA accepted Novocure GmbH’s premarket approval (PMA) application to use its Tumor Treating Fields (TTFields) technology together with standard systemic therapies to treat non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy. Novocure hopes that the application, under review, will get the green light and the therapy, which uses electric fields to disrupt solid tumors and kill cancer cells, will be on the market in the second half of 2024.
It has been previously demonstrated that genetic variability of thioredoxin reductase 1 (TXNRD1) is associated with aging and age-associated phenotypes. Researchers from MD Anderson Cancer Center have now conducted work to assess the role of TXNRD1 in regulating tissue aging.
Applying chimeric antigen receptor (CAR) T-cell therapy to T-cell malignancies presents important limitations due to immune suppression caused by T-cell depletion, in addition to CAR T self-killing and CAR T transfection of malignant cells.
RSS
